Flavivirus Entry Inhibitors.

Area of Science:

• Virology
• Infectious Diseases
• Drug Discovery

Background:

• Flaviviruses, transmitted by mosquitoes and ticks, cause millions of illnesses and thousands of deaths annually.
• Despite available vaccines for some flaviviruses, no approved antiviral therapies exist, highlighting a critical unmet medical need.
• Targeting viral entry represents an active area of research for developing novel anti-flavivirus therapies.

Purpose of the Study:

• To review current knowledge on flavivirus entry mechanisms.
• To discuss the application of flavivirus entry inhibition in small molecule drug discovery.
• To compare the advantages and disadvantages of targeting viral entry versus viral replication for flavivirus treatment.

Main Methods:

• Literature review of scientific publications on flavivirus entry mechanisms.
• Analysis of reported small molecules targeting key steps in the flavivirus entry pathway.
• Comparative discussion of therapeutic strategies targeting viral entry versus viral replication.

Main Results:

• Two primary stages of flavivirus entry are targeted by inhibitors: blocking virus-receptor interactions and preventing viral envelope protein conformational changes during fusion.
• Small molecules inhibiting these entry steps have been identified and reported.
• Targeting viral entry offers a distinct therapeutic approach compared to targeting viral replication proteins.

Conclusions:

• Inhibiting flavivirus entry is a viable strategy for developing new antiviral therapies.
• Further research into small molecule inhibitors targeting virus-receptor binding and membrane fusion is warranted.
• Understanding flavivirus entry pathways is crucial for advancing drug discovery efforts against these significant human pathogens.